CAIX

NCC and PeptiDream Announce the First Dosing of 64Cu-PD-32766 in a patient with Clear Cell Renal Cell Carcinoma

Retrieved on: 
火曜日, 6月 4, 2024
Research, Hospitals, Clinical Trials, Biotechnology, Radiology, Health, Pharmaceutical, Science, Oncology, CAIX, Patient, Safety, PET/CT, Pharmacokinetics, National Cancer Center, Renal cell carcinoma, Carbonic anhydrase, Neoplasm, PET, Pharmaceutical industry

National Cancer Center and PeptiDream Inc.:

Key Points: 
  • National Cancer Center and PeptiDream Inc.:
    The National Cancer Center (President: Hitoshi Nakagama) Hospital East (Director: Toshihiko Doi) and PeptiDream Inc., a public Kanagawa, Japan-based biopharmaceutical company (President: Patrick C. Reid, hereinafter “PeptiDream”)(Tokyo: 4587) today announced the dosing of the first patient in the human imaging study of PeptiDream’s 64Cu-PD-32766, a 64Cu-labelled radiopharmaceutical targeting Carbonic Anhydrase IX (CAIX), for patients with clear cell renal cell carcinoma (ccRCC) conducted at the National Cancer Center Hospital East (“the clinical research”).
  • The clinical research, which was approved by the National Cancer Center Japan’s clinical review board in April 2024, is a first-in-human imaging study of 64Cu-PD-32766 conducted in collaboration with the National Cancer Center Japan and PeptiDream.
  • This study is intended to evaluate the safety, pharmacokinetics, and accumulation of 64Cu-PD-32766 in tumors using PET in patients with newly diagnosed, relapsed or suspected relapsed ccRCC.
  • To evaluate the safety, pharmacokinetics, and exposure dose of PET/CT test with 64Cu-PD-32766 in patients with newly diagnosed, relapsed or suspected to have relapsed ccRCC.

EQS-News: Heidelberg Pharma AG: Interim Management Statement on the First Three Months of 2024

Retrieved on: 
金曜日, 5月 3, 2024
USD, Sale, FDA, CFO, ATAC, Multiple myeloma, CAIX, Priority review, Teaching, Food, Research, Depreciation, BCMA, EUR, Biologics license application, Disease, ADC, Research and development, Patient, Chemistry, Supervisory board, BLA, Diagnosis, Marketing, Interim, Bank statement, Clinical trial, ODD, HPHA, Pharmaceutical industry

Ladenburg, Germany, 25 April 2024 - Heidelberg Pharma AG (FSE: HPHA) today reported on the first three months of fiscal year 2024 (1 December 2023 – 29 February 2024) and the Group’s financial figures.

Key Points: 
  • Ladenburg, Germany, 25 April 2024 - Heidelberg Pharma AG (FSE: HPHA) today reported on the first three months of fiscal year 2024 (1 December 2023 – 29 February 2024) and the Group’s financial figures.
  • Professor Pahl has been Head of Research & Development at Heidelberg Pharma since 2012 and has been a member of the Executive Management Board since 2016.
  • The Heidelberg Pharma Group – as of the reporting date comprising Heidelberg Pharma AG and its subsidiary Heidelberg Pharma Research GmbH – reports consolidated figures.
  • The complete figures for the interim financial statements can be downloaded from http://www.heidelberg-pharma.com/ ”Press & Investors > Announcements > Financial Reports > Interim management statement on the first three months of 2024".

EQS-News: Heidelberg Pharma Announces Royalty Financing Agreement with HealthCare Royalty for up to USD 115 million

Retrieved on: 
水曜日, 3月 13, 2024
Morgan Stanley, Annual report, FDA, Food, Spacecraft, Sale, BLA, ADC, Telix, CAIX, McDermott Will & Emery, Patient, Diagnosis, HPHA, Phase, PET, Positron emission tomography, Pharmaceutical industry

Ladenburg, Germany, 4 March 2024 – Heidelberg Pharma AG (FSE: HPHA), a clinical stage biotech Company developing innovative Antibody Drug Conjugates (ADCs), and HealthCare Royalty (HCRx) today announced that they have signed a royalty financing agreement.

Key Points: 
  • Ladenburg, Germany, 4 March 2024 – Heidelberg Pharma AG (FSE: HPHA), a clinical stage biotech Company developing innovative Antibody Drug Conjugates (ADCs), and HealthCare Royalty (HCRx) today announced that they have signed a royalty financing agreement.
  • Key terms of the agreement between Heidelberg Pharma and HCRx:
    Following the receipt by HCRx of a maximum cumulative amount, royalty payments will revert to Heidelberg Pharma and HCRx will receive a low single digit royalty tail percentage thereafter
    Prof. Dr. Andreas Pahl, Chief Executive Officer at Heidelberg Pharma, commented: “We are delighted to partner with HealthCare Royalty.
  • This agreement will provide us with a non-dilutive financing based on expected royalty payments from the worldwide sales of ZircaixTM.
  • Heidelberg Pharma will hold a conference call on 25 March 2024 with the publication of the Annual Report.

Phase II OPALESCENCE Study of TLX250-CDx in Triple Negative Breast Cancer to be Presented at SABCS

Retrieved on: 
水曜日, 11月 29, 2023
Research, TLX, Carbonic anhydrase, Breast cancer, IIT, Patient, Triple-negative breast cancer, Congress, ASX, CAIX, Diagnosis, PET, ICO, TNBC, Medical imaging

MELBOURNE, Australia, Nov. 29, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today advises that the completed Phase II OPALESCENCE investigator-initiated trial (IIT) of its carbonic anhydrase IX (CAIX)-targeting positron emission tomography (PET) imaging candidate, TLX250-CDx (89Zr-DFO-girentuximab), in patients with triple-negative breast cancer (TNBC), will be presented at the 2023 San Antonio Breast Cancer Symposium® (SABCS) taking place from December 5-9, 2023.

Key Points: 
  • MELBOURNE, Australia, Nov. 29, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today advises that the completed Phase II OPALESCENCE investigator-initiated trial (IIT) of its carbonic anhydrase IX (CAIX)-targeting positron emission tomography (PET) imaging candidate, TLX250-CDx (89Zr-DFO-girentuximab), in patients with triple-negative breast cancer (TNBC), will be presented at the 2023 San Antonio Breast Cancer Symposium® (SABCS) taking place from December 5-9, 2023.
  • Dr. Caroline Rousseau, Principal Investigator for the OPALESCENCE study (ClinicalTrials.gov ID NCT04758780 ) at the Institut de Cancérologie de l'Ouest (ICO) in St Herblain (France), will deliver top-line results as a poster presentation at 5pm CT on Wednesday December 6.
  • SABCS is the largest and most prestigious scientific gathering on breast cancer research worldwide.
  • Visit http://www.sabcs.org/ for more information on the congress.

Phase II OPALESCENCE Study of TLX250-CDx in Triple Negative Breast Cancer to be Presented at SABCS

Retrieved on: 
水曜日, 11月 29, 2023
Research, TLX, Carbonic anhydrase, Breast cancer, IIT, Patient, Triple-negative breast cancer, Congress, ASX, CAIX, Diagnosis, PET, ICO, TNBC, Medical imaging

MELBOURNE, Australia, Nov. 29, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today advises that the completed Phase II OPALESCENCE investigator-initiated trial (IIT) of its carbonic anhydrase IX (CAIX)-targeting positron emission tomography (PET) imaging candidate, TLX250-CDx (89Zr-DFO-girentuximab), in patients with triple-negative breast cancer (TNBC), will be presented at the 2023 San Antonio Breast Cancer Symposium® (SABCS) taking place from December 5-9, 2023.

Key Points: 
  • MELBOURNE, Australia, Nov. 29, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today advises that the completed Phase II OPALESCENCE investigator-initiated trial (IIT) of its carbonic anhydrase IX (CAIX)-targeting positron emission tomography (PET) imaging candidate, TLX250-CDx (89Zr-DFO-girentuximab), in patients with triple-negative breast cancer (TNBC), will be presented at the 2023 San Antonio Breast Cancer Symposium® (SABCS) taking place from December 5-9, 2023.
  • Dr. Caroline Rousseau, Principal Investigator for the OPALESCENCE study (ClinicalTrials.gov ID NCT04758780 ) at the Institut de Cancérologie de l'Ouest (ICO) in St Herblain (France), will deliver top-line results as a poster presentation at 5pm CT on Wednesday December 6.
  • SABCS is the largest and most prestigious scientific gathering on breast cancer research worldwide.
  • Visit http://www.sabcs.org/ for more information on the congress.

EQS-News: Heidelberg Pharma Reports on First Half-Year 2023 and the Course of Business

Retrieved on: 
木曜日, 7月 13, 2023
State University of New York, AACR, EAP, GCC, Half-life, HPHA, ATAC, SRC, Binghamton University, Multiple myeloma, Clinical trial, State university system, Bone marrow, Cancer, American Association for Cancer Research, FSE, Magenta, Research, ATACS, Sale, Spanish mythology, Amanitin, Data analysis, CAIX, Patient, Antibody-drug conjugate, Microsoft Access, Marketing, CFO, Management, Ethics, ADC, Eli Lilly and Company, Depreciation, Spacecraft, Phase, FDA, Therapy, Market Access Program, Safety, Disease, Pharmaceutical industry, Vaccine, Fine chemical, Generic drug, Cryptocurrency, Telix, Emergence

Ladenburg, Germany, 13 July 2023 - Heidelberg Pharma AG (FSE: HPHA) published today its financial report on the first six months of 2023 (1 December 2022 - 31 May 2023).

Key Points: 
  • Ladenburg, Germany, 13 July 2023 - Heidelberg Pharma AG (FSE: HPHA) published today its financial report on the first six months of 2023 (1 December 2022 - 31 May 2023).
  • HDP-101 (BCMA-ATAC) program: Heidelberg Pharma presented preliminary safety data from the clinical trial with HDP-101.
  • The Heidelberg Pharma Group (Heidelberg Pharma) – comprising Heidelberg Pharma AG and its subsidiary Heidelberg Pharma Research GmbH – reports consolidated figures.
  • The full-year financial guidance issued on 24 March 2023 for the Heidelberg Pharma Group is confirmed at this time.

Philogen Announces Publication of a New Study in Collaboration with Google focused on Machine Learning models applied to DNA-Encoded Chemical Library Technology

Retrieved on: 
火曜日, 3月 28, 2023
Tissue, Antigen, Intellectual property, DNA, Chemical library, Renal cell carcinoma, Dels, Ligand, Research, HIT, Blood, Protein, CAIX, Machine learning, DEL, Carbonic anhydrase, Drug discovery, Artificial intelligence, Neoplasm, Hypoxia, DNA-encoded chemical library, Vaccine, Pharmaceutical industry, Jaden Philogene

Siena, Italy, March 28, 2023 - Philogen S.p.A., a clinical-stage biotechnology company focused on the development of innovative antibody and small molecule ligands, announces the publication of a new study conducted in collaboration with Google focused on the use of Machine Learning models applied to the screening of DNA-Encoded Chemical Libraries (DELs).

Key Points: 
  • Siena, Italy, March 28, 2023 - Philogen S.p.A., a clinical-stage biotechnology company focused on the development of innovative antibody and small molecule ligands, announces the publication of a new study conducted in collaboration with Google focused on the use of Machine Learning models applied to the screening of DNA-Encoded Chemical Libraries (DELs).
  • The technology allows the rapid selection of specific binders (“Phenotype”), physically connected to unique DNA tags (“Genotype”) that work as amplifiable identification barcodes.
  • Philochem has synthesized several DNA-Encoded Chemical Libraries, featuring different designs, that have yielded high affinity and selective binders to a variety of target proteins of pharmaceutical interest.
  • These ligands - human monoclonal antibodies or small organic molecules - are identified using Antibody Phage Display Libraries and DNA-Encoded Chemical Library technologies.